Related Experiment Video
Updated: Jun 10, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Do statins improve heart failure outcome in post-myocardial infarction patients with moderate to severe left
Rajiv Sankaranarayanan1, Sameer Maini, Michael Anthony James
1Manchester Heart Centre, UK. rajiv-s@doctors.org.uk
Insights
Statins significantly improve heart failure (HF) outcomes in post-myocardial infarction patients with reduced ejection fraction. This study found statin use independently reduced mortality and HF readmissions in this high-risk group.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) frequently leads to left ventricular dysfunction and heart failure (HF).
- Statins are widely used post-AMI, but their independent effect on HF outcomes requires further elucidation.
Purpose of the Study:
- To assess the independent influence of statin therapy on heart failure outcomes in patients with moderate to severe left ventricular dysfunction after AMI.
Main Methods:
- Retrospective cohort study of 500 AMI patients (March 2000-March 2002) with ejection fraction <40%.
- Patients were analyzed based on discharge statin use, with a mean follow-up of 5.5 years.
- HF outcomes (mortality, readmissions) evaluated independently of other clinical factors.
Main Results:
- Statin group: 28.5% mortality (median survival 252 days) vs. 53% in no-statin group (median survival 141.5 days; P<.001).
- Fewer HF readmissions (7% vs. 32%; P<.001) and HF deaths (4% vs. 13%; P=.002) in the statin group.
- Multivariate analysis confirmed statins' independent benefit, irrespective of cholesterol, age, sex, other drugs, revascularization, or device therapy (ICD/CRT).
Conclusions:
- Statin therapy demonstrates a significant, independent role in improving heart failure outcomes for post-myocardial infarction patients with impaired left ventricular ejection fraction.
- These findings support the continued use and potential optimization of statin therapy in managing high-risk cardiovascular patients.
Abstract:
The authors conducted this retrospective cohort study to assess the influence of statins on heart failure (HF) outcome by enrolling 500 consecutive acute myocardial infarction patients, majority (339 of 500) with moderate to severe left ventricular dysfunction (ejection fraction <40%) between March 2000 and March 2002 with 5.5-year mean follow-up. They were retrospectively analyzed according to whether they were discharged on a statin, and their HF outcome was evaluated independent of overt clinical ischemic events. Mortality in the statin group was 71 of 249 (28.5%; median survival 252 days) vs 48 of 90 (53%; median survival, 141.5 days; P<.001) in the no-statin group. Univariate analysis showed fewer HF readmissions (statin group, 7% vs no-statin group, 32%; P<.001) and HF deaths (statin group, 4% vs no-statin group, 13%; P=.002). Multivariate analysis by logistic regression showed that these effects due to statins are independent of cholesterol levels, age, sex, drugs, revascularization, and implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy. Statins have an important role in independently improving HF outcome in post-myocardial infarction patients with left ventricular ejection fraction < 40%.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure Drugs: β-Blockers
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care
